Skip to content
type1.science

Omnipod 5 (SmartAdjust AID)

Insulet

The tubeless Omnipod 5 automated insulin delivery system — a waterproof, on-body Pod that runs the SmartAdjust algorithm itself and works with a choice of CGM (Dexcom G6/G7 or Abbott FreeStyle Libre 2 Plus/3 Plus). Since June 2026 the enhanced US algorithm adds an optional 100 mg/dL (5.6 mmol/L) target and keeps users in Automated Mode through prolonged highs. Still a hybrid loop — you announce meals. Two Class I FDA recalls of specific Pod lots in 2026 are the serious caveat.

Available nowStrong evidencehybrid-closed-looptubelessphone-controlOfficial site ↗

The scorecard

Time in range75

Achieved, not just improved: the type 1 pivotal trial reached ~68% time-in-range in children and ~74% in adults, and a 353-person real-world type 1 cohort added +16 points on top of baseline — the same whether paired with Dexcom or Libre.[11]

Hypo protection74

Adults achieved ~1.1% time below 70 mg/dL (3.9 mmol/L) in the pivotal trial (down from 2.0%), and severe-hypo events stayed rare across the two-year extension. In a 12-month real-world study of people with impaired awareness of hypoglycemia, starting Omnipod 5 cut time below 70 mg/dL (3.9 mmol/L) from 2.8% to 1.7% and sensor-detected hypo episodes from 5.4 to 4.0 per week — though their residual hypo burden stayed higher than in people with normal awareness.[5]

Automation level66

Predicts glucose 60 min ahead and micro-doses every 5 min including auto-corrections; the enhanced algorithm, live in the US since June 2026, keeps it auto-correcting through prolonged highs instead of dropping to Manual Mode — but meals are still announced, so it remains a hybrid loop.[4]

Freedom (form factor)92

Fully tubeless and waterproof: the entire system is one small on-body Pod with no tubing and no separate pump to clip, carry or disconnect — among the most discreet and mobile AID form factors available.

Average glucose72

Real-world type 1 HbA1c fell most in those starting highest (−3 mmol/mol overall, −7 mmol/mol if baseline ≥58), independent of which sensor was used.[11]

Low variability68

Continuous five-minute adjustment smooths day-to-day swings; large unannounced meals remain the main residual source of variability in a hybrid system.[12]

Exercise handling66

The Activity feature raises the target to 150 mg/dL for up to 24 h; an RCT showed it cuts insulin and softens exercise glucose drops, though it does not fully prevent lows.[14]

Customizability70

The glucose target is adjustable in 10 mg/dL steps, and the enhanced algorithm — live in the US since June 2026 — extends the range down to an optional 100 mg/dL (5.6 mmol/L), giving six settings from 100 to 150 mg/dL (5.6–8.3 mmol/L), plus the timed Activity target.[4]

Access & cost66

Pharmacy-channel availability in the US, UK and EU, and free CGM choice — including the lower-cost, factory-calibrated FreeStyle Libre sensors — that can widen access.[9]

Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.

The full picture

Omnipod 5 is a tubeless automated insulin delivery (AID) system: a single, waterproof Pod worn on the body holds the insulin and runs the control algorithm itself, paired with a continuous glucose monitor (CGM) of your choice. It is not tied to one sensor — in 2026 it works with Dexcom G6, Dexcom G7, Abbott's FreeStyle Libre 2 Plus and the newer FreeStyle Libre 3 Plus, so people can pick the CGM that suits their cost, form factor and preference without changing the pump, algorithm or app.12

Components

The system is three parts working as one: the tubeless Pod, which delivers insulin through an automatically inserted cannula and runs the control algorithm on-body; your chosen CGM, which streams glucose readings; and the SmartAdjust algorithm, which every 5 minutes takes a CGM value and trend, predicts where glucose will be 60 minutes ahead, and increases, decreases or pauses insulin toward your target.34 It is controlled by a compatible smartphone or the supplied Controller.2

The enhanced algorithm — now shipped

The FDA cleared a major SmartAdjust update in December 2025 — the biggest since Omnipod 5 launched — and Insulet began the US over-the-air rollout on 3 June 2026, pushed to existing users through the Controller or the smartphone app.56 Two changes matter most: an optional 100 mg/dL (5.6 mmol/L) glucose target, lowering the selectable range to six settings from 100 to 150 mg/dL (5.6–8.3 mmol/L); and fewer interruptions — a new advisory alarm lets the system keep auto-correcting every 5 minutes through prolonged high-glucose events instead of forcing a switch to Manual Mode.54 The same rollout made FreeStyle Libre 3 Plus live as a sensor option in the US, with LibreLinkUp caregiver following.6

Insulet reports real-world data in which type 1 users who moved from a 150 mg/dL (8.3 mmol/L) target to a 110 mg/dL (6.1 mmol/L) target gained a median 11.8 percentage points of time-in-range, with time below range rising only 0.23 points.6 That is company-reported real-world data rather than a peer-reviewed trial, so treat the size of the effect as indicative — but the direction (a lower target buys more time-in-range without a meaningful hypoglycemia penalty) is consistent with how the pivotal trial's customizable targets behaved.7

Recalls you should know about (2026)

Omnipod Pods — the same Pods this system runs on — were the subject of two separate Class I FDA recalls in 2026, the FDA's most serious category: a tear in the Pod's internal tubing, classified 29 April 2026, and a tear in the cannula just above the skin, classified 2 July 2026.89 They are different defects, and both cause insulin under-delivery. The part that matters most for day-to-day safety: in both cases the under-delivery may happen without triggering any alarm.89 As of the FDA notices, Insulet had reported 29 serious injuries for the tubing defect and 24 for the cannula defect, with no deaths.89

Both recalls are lot-specific — not every Pod is affected. Check your lot numbers with Insulet, which is replacing affected Pods free of charge, and talk to your clinic before changing anything about your therapy.9 Practically, this means unexplained highs on Omnipod deserve a Pod change and a ketone check rather than a correction bolus alone. Full detail, including dates and scope, is on the Omnipod 5 pump record.

Does the sensor change the results?

No. A real-world study of 353 adults that directly compared sensors found that the choice of CGM (Dexcom G6 vs FreeStyle Libre 2 Plus) slightly changed time spent in full automated mode (94% vs 96%) but did not change the likelihood of improving time-in-range or HbA1c — Omnipod 5 use was tied to a +16-point time-in-range gain regardless of sensor, greatest in those who started highest.10

Glycemic outcomes (achieved)

In the 3-month type 1 pivotal trial, time-in-range (70–180 mg/dL / 3.9–10.0 mmol/L) reached ~68% in children and ~74% in adults; HbA1c fell 0.71% and 0.38% respectively; and adults cut time below 70 mg/dL (3.9 mmol/L) from 2.0% to 1.1%.7 Two-year extension data showed these gains were maintained, with users in automated mode ~96% of the time.11

A July 2026 meta-analysis of four randomized trials of tubeless hybrid closed-loop systems (n=514) found +15.31 percentage points of time-in-range and −0.46% HbA1c versus standard care.12 Note what that number is and isn't: it is an improvement over the comparator, not a level people reached — and how big an improvement looks depends on how badly the comparison group was doing. This site scores AID systems on the levels actually achieved, so the meta-analysis strengthens the confidence in the evidence base without moving the time-in-range score.

Hypoglycemia, including impaired awareness

Impaired awareness of hypoglycemia — losing the warning symptoms of a low — is one of the most dangerous complications of type 1 diabetes, and it is exactly the group an AID system should help most. A 12-month real-world study published in July 2026 followed people with impaired awareness who started Omnipod 5: time below 70 mg/dL (3.9 mmol/L) fell from 2.8% to 1.7%, and sensor-detected hypoglycemia episodes fell from 5.4 to 4.0 per week.13 The honest caveat is in the same paper: even after a year on the system, their residual hypoglycemia burden remained higher than in people with normal hypoglycemia awareness. Omnipod 5 reduces the problem; it does not erase it.

Automation level

This is a hybrid closed loop. It automates background insulin and delivers automatic correction micro-boluses for highs, but you still announce meals and count carbohydrates to bolus.3 It is not fully closed-loop — that step is reserved for the successor Omnipod 6.

Exercise

The Activity feature raises the target to 150 mg/dL (8.3 mmol/L) for a chosen period up to 24 hours.14 In a randomized crossover trial, enabling it before exercise reduced insulin delivery and softened the glucose drop versus standard auto mode, though it did not eliminate hypoglycemia — so extra carbohydrate is still advised.15

Form factor

Omnipod 5's defining advantage is freedom: the whole system is one small, tubeless, waterproof Pod. There is no tubing to catch or kink and no separate pump body to clip, carry or disconnect for showering, swimming or sport — the most discreet and mobile form factor among mainstream AID systems.2

Ages, indications and access

Omnipod 5 is indicated from age 2 and available through the pharmacy channel in the US, UK and EU.2 Free CGM choice — including the lower-cost, factory-calibrated FreeStyle Libre sensors — is a practical access advantage.1

The guideline backdrop changed in favour of every system in this category. The ADA Standards of Care in Diabetes—2026 now make automated insulin delivery the preferred insulin delivery method in type 1 diabetes — ahead of multiple daily injections, plain pump therapy and sensor-augmented pumps — at evidence grade A (Recommendation 7.25a).16 The same section supports starting CGM, a pump or AID early, including at diagnosis (7.8), and states there should be no requirement of a C-peptide level, islet autoantibodies, or any minimum duration of insulin treatment before initiating a pump or AID (7.8a).16 Those prerequisites have historically been used as access gates by payers and clinics, so this matters practically, not just rhetorically. To be precise about what it does and doesn't say: the ADA endorses AID as a modality and says the choice of system should follow the individual's circumstances and preferences — it does not prefer Omnipod 5, or any other product, over its competitors.16

References

  1. Insulet (Omnipod). Omnipod 5 & CGM Sensor Integrations — compatible with Dexcom G6, Dexcom G7, FreeStyle Libre 2 Plus and FreeStyle Libre 3 Plus. https://www.omnipod.com/what-is-omnipod/omnipod-5/sensors ↩ ↩2

  2. Insulet Corporation. Omnipod 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S. (Nov 2024) — three sensor choices; pharmacy-channel availability; smartphone control. https://investors.insulet.com/news/news-details/2024/Insulet-Announces-Omnipod-5-System-is-Now-Compatible-with-Abbotts-FreeStyle-Libre-2-Plus-Sensor-in-the-U.S/default.aspx ↩ ↩2 ↩3 ↩4

  3. Insulet. Omnipod 5 FAQs: The Omnipod 5 Algorithm (SmartAdjust) — predicts glucose 60 minutes ahead and adjusts every 5 minutes. https://www.omnipod.com/current-podders/resources/omnipod-5/faqs/smartadjust-technology ↩ ↩2

  4. Insulet. Omnipod 5 Algorithm Enhancement & FreeStyle Libre 3 Plus Integration FAQs (HCPs) — SmartAdjust adjusts every 5 min (up to 12 autocorrections/hour); new Check Blood Glucose Advisory Alarm keeps users in Automated Mode during highs; adds Libre 3 Plus. https://www.omnipod.com/hcp/algorithm-enhancement-faq ↩ ↩2

  5. Insulet Corporation. Insulet Announces FDA 510(k) Clearance of Omnipod 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience — optional 100 mg/dL target; stays in Automated Mode through prolonged highs; US rollout first half of 2026 (announced Dec 4, 2025). https://investors.insulet.com/news/news-details/2025/Insulet-Announces-FDA-510k-Clearance-of-Omnipod-5-Algorithm-Enhancements-that-Redefine-Insulin-Delivery-and-Simplify-the-Pod-Experience/default.aspx ↩ ↩2

  6. Insulet Corporation. Insulet Announces U.S. Rollout of Enhanced Omnipod 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor (June 3, 2026) — over-the-air rollout via Controller or app; optional 100 mg/dL target (six settings, 100–150); stays in Automated Mode through prolonged highs; Libre 3 Plus live in the US with LibreLinkUp caregiver following; company-reported median +11.8-point time-in-range gain in type 1 users moving from a 150 mg/dL to a 110 mg/dL target (time below range +0.23 points). https://investor.insulet.com/news/news-details/2026/Insulet-Announces-U-S--Rollout-of-Enhanced-Omnipod-5-Algorithm-and-Expands-Compatibility-with-Abbotts-FreeStyle-Libre-3-Plus-Sensor/default.aspx ↩ ↩2 ↩3

  7. Brown SA, et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care (2021); 44(7):1630-1640. https://doi.org/10.2337/dc21-0172 ↩ ↩2

  8. US Food & Drug Administration. Insulin Pump Recall: Insulet Removes Certain Omnipod 5 Pods (Early Alert Mar 18, 2026; classified as a Class I recall Apr 29, 2026; tear in the Pod's internal tubing causing insulin under-delivery; 29 serious injuries and no deaths as of Apr 17, 2026). https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/insulin-pump-recall-insulet-removes-certain-omnipod-5-pods ↩ ↩2 ↩3

  9. US Food & Drug Administration. Insulin Pump Recall: Insulet Removes Omnipod Pods (Early Alert Jun 4, 2026; classified as a Class I recall Jul 2, 2026; cannula tear just above the skin; under-delivery "may happen without triggering any alert"; affects Omnipod 5, Omnipod DASH and Omnipod (Eros) Pods from specific lots; Insulet is replacing affected Pods free of charge; 24 serious injuries and no deaths as of May 20, 2026). https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/insulin-pump-recall-insulet-removes-omnipod-pods ↩ ↩2 ↩3 ↩4

  10. Stimson RH, et al. Impact of Omnipod 5 automated insulin delivery on continuous glucose monitoring metrics and predictors of improvement in time in range. Diabet Med (2025); 42(11):e70137. https://doi.org/10.1111/dme.70137 ↩

  11. Criego AB, et al. Two Years with a Tubeless Automated Insulin Delivery System. Diabetes Technol Ther (2024); 26(1):11-23. https://doi.org/10.1089/dia.2023.0364 ↩

  12. Lei M, et al. Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials — 4 RCTs, n=514; time-in-range +15.31 points, HbA1c −0.46% vs standard care. Diabetes Obes Metab (2026). https://doi.org/10.1111/dom.71061 ↩

  13. Goodman IR, et al. Effects of the Omnipod 5 Hybrid Closed-Loop System in People With Type 1 Diabetes With Impaired Awareness of Hypoglycemia. Diabetes Care (2026). https://doi.org/10.2337/dc26-0422 ↩

  14. Insulet. Optimizing the Omnipod 5 Activity Feature for Your Patients. https://www.omnipod.com/hcp/blog/tips-guidelines/activity-feature-tips ↩

  15. Turner LV, et al. Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled Trial. Diabetes Care (2025); 48(9):1598-1606. https://doi.org/10.2337/dc25-0141 ↩

  16. American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1):S150–S165 (published online 8 December 2025) — Rec. 7.25a (grade A): AID is the preferred insulin delivery method over MDI, CSII and sensor-augmented pumps in people with type 1 diabetes, with the choice of system based on the individual's circumstances, preferences and needs; Rec. 7.8 (C): consider early initiation, including at diagnosis; Rec. 7.8a: no requirement of C-peptide level (B), islet autoantibodies (B) or duration of insulin treatment (C) before initiating CSII or AID. https://pmc.ncbi.nlm.nih.gov/articles/PMC12690173/ ↩ ↩2 ↩3

What's next for this

  • →Successor Omnipod 6 with an adaptive-learning algorithm and one universal Pod across Dexcom and Libre · targeted 2027

Sources

  1. [1]Insulin Pump Recall: Insulet Removes Omnipod Pods (Class I) · regulatory · 2026-07-02 — Cannula tear just above the skin causing insulin under-delivery that may happen without triggering any alarm; affects Omnipod 5, Omnipod DASH and Omnipod (Eros) Pods from specific lots.
  2. [2]Insulin Pump Recall: Insulet Removes Certain Omnipod 5 Pods (Class I) · regulatory · 2026-04-29 — Earlier, separate defect — a tear in the Pod's internal tubing, also causing under-delivery that can go unalarmed.
  3. [3]Insulet Announces FDA 510(k) Clearance of Omnipod 5 Algorithm Enhancements (optional 100 mg/dL target; stays in Automated Mode during prolonged highs; US rollout first half of 2026) · manufacturer · 2025-12-04
  4. [4]Insulet Announces U.S. Rollout of Enhanced Omnipod 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor (over-the-air update from 3 June 2026; optional 100 mg/dL target, six settings 100–150; stays in Automated Mode through prolonged highs) · manufacturer · 2026-06-03
  5. [5]Goodman IR, et al. Effects of the Omnipod 5 Hybrid Closed-Loop System in People With Type 1 Diabetes With Impaired Awareness of Hypoglycemia. Diabetes Care 2026 · peer-reviewed · 2026-07-10
  6. [6]Lei M, et al. Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials (4 RCTs, n=514; time-in-range +15.31 points and HbA1c −0.46% vs standard care). Diabetes Obes Metab 2026 · peer-reviewed · 2026-07-06
  7. [7]American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1):S150–S165 (Rec. 7.25a, grade A — AID is the preferred insulin delivery method in type 1 diabetes) · peer-reviewed · 2025-12-08
  8. [8]Omnipod 5 Algorithm Enhancement & FreeStyle Libre 3 Plus Integration FAQs (SmartAdjust adjusts insulin every 5 minutes; new Check Blood Glucose Advisory Alarm keeps users in Automated Mode) · manufacturer
  9. [9]Omnipod 5 & CGM Sensor Integrations — Dexcom G6, Dexcom G7, FreeStyle Libre 2 Plus and FreeStyle Libre 3 Plus · manufacturer
  10. [10]Brown SA, et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care 2021;44(7):1630-1640 · peer-reviewed · 2021-07-01
  11. [11]Stimson RH, et al. Impact of Omnipod 5 automated insulin delivery on continuous glucose monitoring metrics in type 1 diabetes (real-world, n=353; +16 points time-in-range, sensor-independent). Diabet Med 2025;42(11):e70137 · peer-reviewed · 2025-09-01
  12. [12]Criego AB, et al. Two Years with a Tubeless Automated Insulin Delivery System. Diabetes Technol Ther 2024;26(1):11-23 · peer-reviewed · 2024-01-01
  13. [13]Insulet's Updated Omnipod 5 Algorithm Approved by FDA (Beyond Type 1) · news
  14. [14]Turner LV, et al. Use of the Omnipod 5 Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise: a Randomized Controlled Trial. Diabetes Care 2025;48(9):1598-1606 · peer-reviewed · 2025-09-01